How's the longevity market doing these days?

Is new money still coming into the longevity market now?

Yes, the longevity market is still getting funded, but the easy-check era is over.

In the last twelve months, the biggest longevity checks have gone to companies with either a regulated therapeutic path or a scaled diagnostic platform.

NewLimit’s $435 million Series C, Life Biosciences’ clinical push, Loyal’s dog-longevity financing, Function Health’s $298 million Series B, Prenuvo’s $120 million raise, and Viome’s $25 million internal round all point in the same direction: capital is still available when the company can attach longevity to medicine, data, or infrastructure.

Deal count is not expanding in the same way. We tracked 31 disclosed deals in 2025, totaling roughly $2.2 billion, versus only five disclosed deals and about $234 million from January to May 2026 before the NewLimit round changed the picture.

That means the market is not spraying money across every biohacking pitch. It is concentrating into a smaller number of companies that look closer to clinical platforms than consumer fads.

That concentration is the real story. A weak market would show falling dollars and falling ambition. This market shows fewer casual bets, but very large conviction rounds where the biology, regulatory story, or distribution is strong enough.

If you want more recent data on this point, please see our latest longevity market report.

Are longevity startups finally testing real interventions in humans lately?

Yes, longevity biotech has crossed a serious line recently: it is no longer only preclinical storytelling.

We now have several recent examples of aging-biology companies moving into first-in-human or clinical-stage work.

Life Biosciences dosed the first patient with ER-100 in June 2026, targeting optic neuropathies such as glaucoma and NAION through epigenetic restoration. Retro Biosciences moved RTR242, an oral autophagy-focused drug, into Phase I. NewLimit’s new financing is explicitly tied to moving its epigenetic reprogramming program toward human testing.

That is a meaningful change because these are not generic “anti-aging pills” but narrow entry points into aging biology: optic nerve damage, autophagy decline, liver-cell reprogramming, metabolic dysfunction, and neurodegeneration-adjacent biology. The companies are learning to translate the language of aging into the language of clinical development.

We can be more confident here than a year ago. The market is still early, but it has moved from “does this work in mice?” to “can this be made safe enough, targeted enough, and measurable enough in humans?”.

We believe that is exactly the transition serious biotech investors were waiting for.

Are the big reprogramming bets still fantasy, or are they becoming investable now?

Cellular reprogramming is still risky, but it has become the highest-conviction corner of longevity biotech.

The strongest recent proof is NewLimit. A $435 million Series C at a reported $3.1 billion valuation is not a casual “future of aging” bet. It came after the company reported age-reversal signals in old human liver cells and framed the raise around advancing a first clinical candidate.

Life Biosciences adds a second signal: ER-100 has now entered a Phase 1 trial for optic neuropathies. Altos Labs remains harder to read from the outside, but its original $3 billion launch and continued public movement around cell rejuvenation keep reprogramming as the category’s prestige magnet.

The risk is still very real. Reprogramming has a safety problem by design: pushing cells toward a more youthful state can also create proliferation and cancer concerns if control is poor. That is why the smartest companies are not starting with whole-body rejuvenation. Instead, they are choosing constrained settings where local delivery, tissue specificity, and clear endpoints make the risk more manageable.

If you want more recent data on this point, please see our latest longevity market report.

Are consumer longevity clinics still growing these days, or is the hype fading?

Consumer longevity clinics are still growing, but the market is splitting between serious prevention and expensive theater.

Demand is clearly not gone. Longevity medicine has moved into mainstream consumer health, with reporting describing hundreds of U.S. clinics and high-end programs that can cost tens of thousands of dollars. Function Health is a cleaner signal than most clinic anecdotes: it says members have completed more than 50 million lab tests since 2023, it gives access through roughly 2,000 Quest locations, and it raised $298 million at a $2.5 billion valuation. Prenuvo is another signal, with 150,000 scans reported since 2018, rapid recent scan growth, and a $2,500 price point that still attracts enough demand to support geographic expansion.

But the evidence layer is not keeping up with the commercial layer. NAD+ infusions, ozone, peptides, chelation, hyperbaric oxygen, and broad “age reversal” protocols are still sold faster than they are validated. Full-body MRI has a similar tension: Prenuvo reports meaningful detection rates, but radiologists and lawsuits highlight false positives, false reassurance, and unclear survival benefit.

This clinic growth proves that consumers want preventive control, especially when the traditional healthcare system feels reactive.

And the investable wedge is probably the trusted operating system around prevention: standardized tests, longitudinal tracking, physician interpretation, risk stratification, follow-up pathways, and clear rules about what the data can and cannot say.

Are biological-age tests becoming real infrastructure now?

Yes, biological-age testing is becoming infrastructure, but the market is moving beyond vanity age scores.

The most interesting recent shift is from “What is my biological age?” to “Which organ system is aging faster, and can we change the trajectory?”.

New proteomic clocks built on UK Biobank-scale data now estimate organism-wide and organ-specific aging from blood proteins, with validation across tens of thousands of participants and international cohorts. Healthspan proteomic scores are also being linked to mortality and major age-related diseases such as heart failure, cancer, dementia, stroke, COPD, and diabetes.

Epigenetic clocks are also improving, but the direction is more nuanced. New models are trying to reduce noise by combining clock types, graph structures, sequence context, and multi-omics inputs. That tells us something important: the field itself knows that a single biological-age number is too crude. The next version is multi-organ, multi-omics, disease-linked, and longitudinal.

The market implication is clear. Biological-age testing is not especially defensible when sold as a one-time curiosity. It becomes valuable when it helps a clinic, payer, employer, pharma company, or trial sponsor decide who is at risk, which intervention to use, and whether the intervention actually moved biology in the right direction.

Are GLP-1s eating the longevity market right now?

Yes, GLP-1s are reshaping the longevity market more than most longevity startups are.

This is one of the clearest current signals. Semaglutide now has large-scale evidence across weight, cardiovascular outcomes, kidney endpoints, diabetes prevention, inflammation-adjacent biology, and, more recently, epigenetic-aging markers in a randomized post-hoc trial. The new biological-aging study was small and specific to adults with HIV-associated lipohypertrophy, but it matters because it is randomized, placebo-controlled, and tied to aging biomarkers rather than influencer claims.

The comparison is brutal for the rest of the market. Many longevity products are still trying to prove that a marker moved in 30 or 100 people. GLP-1s already have outcome trials showing fewer cardiovascular events and kidney benefit in large populations. Even where the story failed, such as oral semaglutide not slowing Alzheimer’s progression in two late-stage trials, the failure is useful because it sets a higher evidence bar.

Our read is that GLP-1s are turning longevity into mainstream chronic-disease prevention. They also make the startup landscape harder. A new healthspan intervention now has to explain whether it competes with GLP-1s, complements them, reduces their side effects, personalizes their use, or addresses aging pathways they do not touch.

If you want more recent data on this point, please see our latest longevity market report.

Is the longevity supplement boom still credible these days?

The supplement side of the longevity market is still commercially alive, but it is losing scientific status.

NAD+, NMN, NR, spermidine, fisetin, and peptide-adjacent products still have consumer pull because the story is simple and emotionally powerful: aging depletes something, so replace it. The regulatory picture has also revived some commercial energy. NMN regained a clearer dietary-supplement path in the U.S., while 2026 peptide-compounding debates reopened attention around compounds used by longevity clinics.

But the evidence gap is the problem. Many supplement studies show biomarker movement, tolerability, or short-term metabolic changes. They rarely show lower disease incidence, better physical function at scale, or longer healthy lifespan. IV NAD+ is especially vulnerable because the mechanistic story does not automatically translate into cellular uptake or clinical benefit.

This does not mean supplements disappear but it does mean they become the low-defensibility revenue layer of longevity. The category can still build brands and cash flow, but it is no longer where the market’s deepest credibility is forming.

The sharper opportunity is evidence-ranked supplementation inside a broader diagnostic and medical workflow. It’s not standalone “anti-aging stack” marketing.

Is pet longevity becoming real faster than human longevity?

Yes, pet longevity may reach a regulated market before human longevity does.

Loyal is the key signal. Its LOY-002 program has now had the FDA accept the Target Animal Safety section after earlier progress on reasonable expectation of effectiveness. The company’s STAY study includes around 1,300 dogs, with field safety data from more than 400 animals already part of the package. That is a very different evidence posture from most consumer longevity products.

The business logic is also stronger than people assume. Dogs age faster than humans, so studies can read out sooner. Owners are emotionally motivated and used to out-of-pocket spending. The regulatory path for veterinary drugs can be more practical than proving lifespan extension in healthy humans. And if a daily pill for senior dogs gets conditionally approved around healthy lifespan extension, it creates a precedent investors will study closely.

Pet longevity is therefore more than a cute submarket. We should look at it as a regulatory sandbox for healthspan drugs. The first product that makes “longevity medicine” feel real to consumers may not be for humans at all.

Are old-school senolytics still hot now?

No, to be honest, senolytics have lost momentum, and the market is much less patient with mechanism-first aging stories.

UNITY Biotechnology is the obvious warning signal, but it is not the only one. UNITY moved into restructuring and strategic alternatives after its ASPIRE program disappointed and the company shifted toward conserving capital.

BioAge’s azelaprag failure was not technically a senolytic story, but it sent the same message: aging biology plus a fashionable indication like obesity does not protect a program if human safety breaks. AbbVie ending its long Calico collaboration adds another institutional signal that large pharma patience for open-ended aging R&D is limited.

The deeper pattern is that aging mechanisms no longer get a free pass. Senescence, autophagy, inflammation, nutrient sensing, and epigenetic drift are all biologically plausible. The market now wants a translation package: endpoint, population, dosing window, safety margin, and biomarker-to-outcome bridge.

That is a healthy correction. Senolytics are not dead as biology, but the investment story is colder now. The next credible senolytic company will need to look less like a broad aging-platform company and more like a focused clinical developer with one painful, measurable indication.

If you want more recent data on this point, please see our latest longevity market report.

Are regulators finally opening the door for aging drugs?

Regulators are not approving “aging” yet, but the policy door is opening wider than before.

This is a subtle but important change. The FDA still does not treat aging itself as a drug indication, which forces companies to pursue age-related diseases, organ-specific decline, frailty-adjacent endpoints, or veterinary pathways. That constraint remains one of the biggest structural limits on human longevity drugs.

But lately the conversation has become more formal. The Reagan-Udall Foundation held a May 2026 public meeting on regulatory constructs for gerotherapeutic drug, biologic, and device development. Longevity advocacy groups have also become more active in Washington, and state-level efforts have started to reduce barriers for some experimental therapies under controlled frameworks. Peptide policy is moving too, with 2026 FDA compounding-list reviews bringing several clinic-used compounds back into regulatory discussion.

We should not overstate this. There is no clean FDA pathway for “extend human lifespan” today.

Still, the regulatory conversation is moving from fringe biohacking toward formal policy design.

That matters because the market cannot fully institutionalize until aging biology has recognized endpoints, acceptable biomarkers, and predictable approval paths.

Is AI in longevity actually useful now, or mostly pitch-deck decoration?

AI is useful in longevity when it touches biology or clinical workflow. However, generic longevity coaching is already commoditized.

The weak version is a chatbot that tells people to sleep, lift weights, eat protein, and check bloodwork. That is clearly not a venture-scale moat. The stronger version is starting to appear in three places: biomarker interpretation, drug discovery, and experimental design.

Function Health is a good example on the workflow side. It is not just selling lab tests but actually trying to turn repeated bloodwork, MRI data, physician review, and AI-assisted interpretation into a consumer health operating system. Retro Biosciences is a different example: its OpenAI-linked protein-design work and autophagy program show how AI can sit closer to therapeutic discovery. Biological-age research is also becoming more machine-learning-heavy, with graph neural networks, multi-omics models, and organ-specific proteomic clocks improving how aging signals are detected.

The useful distinction is this: AI alone is not a longevity product. Rather, AI becomes valuable when it reduces biological uncertainty, makes dense testing interpretable, or speeds the loop between experiment and clinical candidate. The more the market matures, the less patience it will have for AI wrappers around generic wellness advice.

Is the longevity market still mostly for rich biohackers?

No, but the mass market is forming through diagnostics and metabolic medicine before true longevity drugs.

The old image of longevity was a wealthy person paying for plasma, peptides, scans, and supplements. That segment still exists, but it is no longer the whole market. Function Health’s hundreds of thousands of members, Quest distribution, and low-friction lab model point to a broader preventive-health consumer. GLP-1 adoption pulls millions of people into a healthspan-adjacent conversation without using longevity branding. Whole-body MRI remains expensive, but its expansion shows consumers are willing to pay for early detection when the value proposition feels concrete.

The catch is that affordability and evidence still decide how far this goes. A $2,500 scan, a concierge longevity clinic, or a repeated multi-omics panel is not mass medicine yet. GLP-1s are closer to mass medicine because they already have disease indications, insurance pathways, and measurable outcomes.

So, how is the longevity market doing these days?

The longevity market is doing well now, because it’s getting more evidence-driven.

The market has clearly not died. Fresh capital is still coming in, first-in-human milestones are arriving, GLP-1s are dragging healthspan into mainstream medicine, pet longevity is nearing a real regulatory precedent, and biological-age testing is moving from gimmick toward infrastructure. That is a strong set of signals.

But this is no longer a market where broad “anti-aging” language is enough. The weak parts are being exposed: senolytics without clinical proof, supplements without outcome data, clinics selling protocols faster than evidence supports them, and AI products that do not touch real biology.

As seen above, the same market can fund a $435 million reprogramming bet and punish a mechanism-first biotech when human translation disappoints.

So, clearly, the longevity market is healthy, but the center of gravity has moved. The opportunity is not in selling immortality but in building the measurable healthspan stack: regulated therapeutics, organ-specific biomarkers, prevention workflows, GLP-1-adjacent metabolic care, pet-longevity precedents, and trusted clinical interpretation.

If you want more recent data on this point, please see our latest longevity market report.

Check	Trend	Explanation
Fresh longevity funding	Up	The money is still there, but it is concentrating into fewer, stronger platforms. Large recent rounds favor regulated therapeutics, diagnostics, and infrastructure rather than loose anti-aging brands.
Human clinical translation	Up	Life Biosciences, Retro, and NewLimit show the field moving into or toward human studies. That makes longevity biotech more concrete than it was during the mouse-data phase.
Cellular reprogramming	Up	Reprogramming remains high-risk, but it is attracting the largest conviction checks. The strategy is becoming more investable because companies are narrowing into specific tissues and diseases.
Consumer clinics	Mixed	Demand is rising, but proof quality is uneven. The strongest opportunity is not the clinic itself, but the trusted measurement and follow-up layer around prevention.
Biological-age testing	Up	The category is moving from vanity scores toward multi-organ and multi-omics infrastructure. It becomes valuable when tied to decisions, not when sold as a one-time number.
GLP-1 healthspan crossover	Up	GLP-1s are the strongest near-term bridge between mainstream medicine and longevity. They raise the evidence bar for every other healthspan intervention.
Supplements and NAD	Mixed	The market is commercially alive, but scientific defensibility is weaker. Supplements work better as part of a medically supervised stack than as standalone longevity claims.
Pet longevity	Up	Loyal’s FDA progress makes dogs one of the clearest regulated paths for lifespan-extension products. This could become the first real commercial proof point for longevity drugs.
Senolytics and older mechanisms	Down	Clinical and corporate setbacks have cooled the category. Mechanism-first aging stories now need sharper endpoints and stronger human translation.
Regulation	Mixed	Aging is still not an FDA indication, but formal gerotherapeutic-policy discussions are becoming more serious. The direction is positive, but the pathway is not solved.
AI longevity	Up	AI is useful when attached to biomarkers, drug discovery, or clinical workflow. Standalone AI wellness coaching is already too generic to matter.
Mass-market adoption	Up	Longevity is spreading through diagnostics, GLP-1s, and preventive care rather than true anti-aging drugs. That makes the market broader, but also more medical and evidence-driven.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.